REstore Working Ability in RheumatoiD Arthritis

Rheumatoid Arthritis Clinical Trial

— REWARD  

Official title:

The Effect of Six Months Adalimumab Treatment on Sick Leaves and Retirement in Patients With Rheumatoid Arthritis Who Are at a Risk of Losing Their Ability to Work

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01405326
• Other study ID #: RE100002011
• Status: Recruiting
• Phase: Phase 4
• First received: June 30, 2011
• Last updated: July 28, 2011
• Start date: May 2011
• Est. completion date: March 2013

Study information

• Verified date: July 2011
• Source: The Rheumatological Center of Helsinki
• Contact: Kari K Eklund, MD
• Phone: +358405832866
• Email: kari.eklund[@]welho.com
• Is FDA regulated: No
• Health authority: Finland: Finnish Medicines Agency
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to assess whether a 6-month treatment with adalimumab added on the treatment with conventional antirheumatic drugs (DMARD) will decrease the number of days on sick leave compared to placebo. In addition, the cost-effectiveness and cost-utility of the intervention compared to the conventional treatment is evaluated, and the patients who benefit most are characterized.

Description:

In spite of the improved medical treatment, rheumatoid arthritis (RA) is still causing both significant morbidity and marked loss of work productivity. Short periods of work inability, i.e., sick leaves represent a significant part of the socioeconomic burden of RA. The study is a randomized, controlled double blind multi-center study. 160 patients of 25 to 55 years of age with recent-onset (≤2 years from diagnosis) RA who have been treated with a combination of conventional antirheumatic drugs but have an inadequate response to treatment and are at the risk of losing their ability to work, are enrolled. The patients should be biologic-naïve. Their RA should be active, but not so active that the conventional criteria for biologic therapy would be fulfilled. The subjects are randomized at 1:1 ratio to receive either adalimumab (40 mg every two weeks) or placebo for 6 months added on their concurrent antirheumatic therapy. The RA-related sickness absence and clinical response will be evaluated.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 160
• Est. completion date: March 2013
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 25 Years to 55 Years

Eligibility

Inclusion Criteria:

1. Diagnosis of RA according to the 1987 revised American College of Rheumatology (ACR) criteria

2. Time from diagnosis of RA < 2 years

3. Age 25-55 years

4. Active RA with at least 3 active joints (tender and/or swollen joints)

5. Stable DMARD combination treatment for more than 3 months

6. At least one of the following

• Rheumatoid factor positive

• One or more erosions in x-rays of the hands and feet

• Anti-citrulline antibodies positive

7. At least other of the following

• HAQ-index 0.5 or more

• Patient or physician evaluation of RA activity >25 mm (VAS 0-10 cm)

8. Patient has been steadily in work-life for at least one year and is currently working or on sick- leave but not applying for pension

9. Patient feels that he/she will likely have to be off-work during the following 6 months due to his/her RA

10. Patient must be willing and able to provide written informed consent for the trial

11. Each female subject must agree to use a medically accepted method of contraception while receiving study medication

Exclusion Criteria:

1. A subject must not have a history of biological drug use for RA

2. A subject must not have evidence of active or latent tuberculosis,

3. A subject must not have any history of lymphoproliferative disease or malignancy within the previous 5 years

4. A subject must not have any other condition, that according to the investigator's judgment makes him or her non-eligible for anti-TNF use

5. A subject must not have any inflammatory rheumatic disease other than RA

6. A subject must not have received any other investigational agents within 30 days prior to baseline visit, and must not receive them during the current trial

7. A female subject must not be pregnant or breast-feeding or planning pregnancy during the study

8. A subject must not have had a major surgery within one month prior to study entry and must not have a scheduled operation during the 6-month follow up

9. A subject must not have any clinically significant condition or situation, other than the condition being studied, that in the opinion of the investigator would interfere with the optimal participation in the trial.

10. A subject must not fulfill the criteria for reimbursement for biologics for RA and he/she would not normally be prescribed a biological drug according to physicians discretion and national treatment guidelines

11. A patient must not be currently on reimbursed rehabilitation period, or such period must not be scheduled for the next six months

Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator)

Related Conditions & MeSH terms

• Arthritis
• Arthritis, Rheumatoid
• Rheumatoid Arthritis

Intervention

Biological:
• adalimumab
40mg sc. every two weeks for six months

Locations

Country	Name	City	State
Finland	Helsinki University Central Hopsital	Helsinki
Finland	Lappland Central Hospital	Rovaniemi
Finland	Tampere University hospital, Rheumatology Centre	Tampere
Finland	The Turku Universitry Central Hopsital	Turku

Sponsors (2)

Lead Sponsor	Collaborator
The Rheumatological Center of Helsinki	Abbott

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of lost work days due to RA during the 6-month follow up.		6 months	No
Secondary	Change in health-related quality of life as measured by the EQ-5D index over the 6-month follow up		baseline and 6 months	No
Secondary	Change in functionality assessed by the HAQ over the 6-month follow up		baseline and 6 months	No
Secondary	Change in disease activity measured with DAS28 with CRP and ESR over the 6-month follow up		baseline and 6 months	No
Secondary	Work Productivity and Activity Impairment Questionnaire (WPAI)		6 months	No